Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

62.88 -0.16 (-0.26%)
Streaming Delayed Price Updated: 2:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 587,657
Open 63.15
Bid (Size) 62.86 (3)
Ask (Size) 62.91 (5)
Prev. Close 63.05
Today's Range 62.34 - 63.70
52wk Range 33.32 - 70.75
Shares Outstanding 111,290,699
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire

Performance

YTD
+25.07%
+25.07%
1 Month
+7.50%
+7.50%
3 Month
+20.79%
+20.79%
6 Month
-1.43%
-1.43%
1 Year
+20.72%
+20.72%

More News

Read More
Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Option to Purchase Additional Shares
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Pharmaceuticals's Return On Capital Employed Insights
Via Benzinga
Why Are Apellis Pharmaceuticals Shares Trading Higher Today?
Via Benzinga
What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy?
Via The Motley Fool
Why Apellis Pharmaceuticals Stock Surged This Week
Via The Motley Fool
Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
Via Investor's Business Daily
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Owlet Shares Are Trading Higher By Over 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
FDA Approves SYFOVRE™ (pegcetacoplan injection) as the First and Only Treatment for Geographic Atrophy (GA), a Leading Cause of Blindness
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Appoints Leading Retina Specialist Dr. Caroline Baumal as Chief Medical Officer
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Apellis Submits Marketing Authorization Application to the European Medicines Agency for Pegcetacoplan for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.